Aligos Therapeutics Return On Equity History
| ALGS Stock | USD 6.37 0.02 0.31% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter -0.45 | Current Value -0.45 | Quarterly Volatility 1.29 |
Macro event markers
Latest Aligos Therapeutics Return On Equity Growth Pattern
| Return On Equity | 10 Years Trend |
|
Return On Equity |
| Timeline |
Return On Equity Trend Statistics
Statistical analysis of Aligos Therapeutics' Return On Equity across 8 periods yields a CV of 209.3% (elevated dispersion relative to the mean) and an R-squared of 0.06, consistent with no statistically meaningful linear trend.| Arithmetic Mean | 0.62 | |
| Geometric Mean | 0.92 | |
| Coefficient Of Variation | 209.29 | |
| Mean Deviation | 0.90 | |
| Median | 1.01 | |
| Standard Deviation | 1.29 | |
| Sample Variance | 1.67 | |
| Range | 5.4809 | |
| R-Value | -0.25 | |
| Mean Square Error | 1.67 | |
| R-Squared | 0.06 | |
| Significance | 0.32 | |
| Slope | -0.07 | |
| Total Sum of Squares | 26.78 |
Aligos Therapeutics Return On Equity History
Aligos Therapeutics reports Return On Equity from 2019 through 2026 across 8 observations, beginning at 1 and ending at 0.Correlation of Return On Equity With Other Accounts
Cross-account correlations for Aligos Therapeutics' Return On Equity measure how closely related line items have moved together historically. Correlation does not establish cause and effect.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Return On Tangible Assets | -0.27 | -0.29 | |
| Return On Capital Employed | -1.31 | -1.37 | |
| Return On Assets | -27.00% | -29.00% |
Methodology, Assumptions & Data Sources
The Return On Equity trend for Aligos Therapeutics is contextualized below with regression and dispersion statistics. Sequential period comparisons surface inflection points that rolling averages can obscure. As a technology-driven company, Aligos Therapeutics' Return On Equity reflects ownership capital supporting the operating base.
Aligos Therapeutics values are built from periodic company reporting and market reference feeds, with reporting definitions aligned before display. Analyst projections are included when active coverage applies. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board